Over the past 12 months, Oncolytics Biotech insiders bought $362,615 of stock on the open market (404.28K shares) and made no open-market sales.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Bernd R. Seizinger | Director | 566,991 | 0 | 566,991 | 26.4% | 13 Feb, 2026 |
| 2 | Wayne Pisano | Director | 492,414 | 0 | 492,414 | 23.0% | 13 Feb, 2026 |
| 3 | Kirk Look | Chief Financial Officer | 287,515 | 0 | 287,515 | 13.4% | 13 Feb, 2026 |
| 4 | Thomas Charles Heineman | Chief Medical Officer | 282,818 | 0 | 282,818 | 13.2% | 13 Feb, 2026 |
| 5 | Allison Hagerman | Vp, Product Development | 115,059 | 0 | 115,059 | 5.4% | 13 Feb, 2026 |
| 6 | Jared Kelly | Chief Executive Officer | 114,050 | 0 | 114,050 | 5.3% | 13 Mar, 2026 |
| 7 | Deborah Margaret Brown | Director | 109,851 | 0 | 109,851 | 5.1% | 13 Feb, 2026 |
| 8 | Patricia S Andrews | Director | 78,128 | 0 | 78,128 | 3.6% | 13 Feb, 2026 |
| 9 | Andrew Aromando | Chief Business Officer | 55,100 | 0 | 55,100 | 2.6% | 13 Feb, 2026 |
| 10 | James T. Parsons | Director | 41,849 | 0 | 41,849 | 2.0% | 13 Mar, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 01 Jun, 2026 | Stephen C. Glover | Director | Acquired A | 96,000 | $0.00 | $0 | 96,000 | Direct |
| 01 Jun, 2026 | Angela Holtham | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 01 Jun, 2026 | Jared Kelly | Chief Executive Officer | Acquired A | 755,000 | $0.00 | $0 | 755,000 | Direct |
| 01 Jun, 2026 | James T. Parsons | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 01 Jun, 2026 | John Bearden Mcadory | Chief Operating Officer | Acquired A | 145,000 | $0.00 | $0 | 145,000 | Direct |
| 01 Jun, 2026 | Kirk Look | Chief Financial Officer | Acquired A | 260,000 | $0.00 | $0 | 260,000 | Direct |
| 01 Jun, 2026 | Allison Hagerman | Chief Technology Officer | Acquired A | 260,000 | $0.00 | $0 | 260,000 | Direct |
| 01 Jun, 2026 | Jonathan Rigby | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 01 Jun, 2026 | Patricia S Andrews | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 01 Jun, 2026 | Wayne Pisano | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 01 Jun, 2026 | Bernd R. Seizinger | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 01 Jun, 2026 | Andrew Aromando | Chief Business Officer | Acquired A | 260,000 | $0.00 | $0 | 260,000 | Direct |
| 01 Jun, 2026 | Thomas Charles Heineman | Chief Medical Officer | Acquired A | 260,000 | $0.00 | $0 | 260,000 | Direct |
| 01 Jun, 2026 | Deborah Margaret Brown | Director | Acquired A | 30,000 | $0.00 | $0 | 30,000 | Direct |
| 11 Mar, 2026 | James T. Parsons | Director | Acquired P | 10,000 | $1.03 | $10.30K | 41,849 | Direct |
| 12 Mar, 2026 | Jared Kelly | Chief Executive Officer | Acquired P | 5,050 | $0.96 | $4.85K | 114,050 | Direct |
| 11 Feb, 2026 | Bernd R. Seizinger | Director | Acquired P | 60,000 | $0.83 | $49.59K | 526,991 | Direct |
| 11 Feb, 2026 | Andrew Aromando | Chief Business Officer | Acquired P | 29,600 | $0.86 | $25.42K | 55,100 | Direct |
| 11 Feb, 2026 | Jared Kelly | Chief Executive Officer | Acquired P | 5,600 | $0.84 | $4.68K | 79,500 | Direct |
| 12 Feb, 2026 | Deborah Margaret Brown | Director | Acquired P | 25,000 | $0.85 | $21.24K | 109,851 | Direct |